Therapeutic Monitoring of Aripiprazole by HPLC with Column-Switching and Spectrophotometric Detection
Open Access
- 1 September 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (9), 1718-1721
- https://doi.org/10.1373/clinchem.2005.049809
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in PsychiatryPharmacopsychiatry, 2004
- Subjective Effects of Slow-Release Bupropion versus Caffeine as Determined in a Quasi-Naturalistic SettingPharmacology, 2004
- Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic functionEuropean Journal of Pharmacology, 2004
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust PharmacologyNeuropsychopharmacology, 2003
- Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2002
- Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]RacloprideNeuropsychopharmacology, 2002
- Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 2000